Avation Medical, an innovative neuromodulation and digital health company pioneering a wearable platform to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI), today announced that Dr. Colin Goudelocke, investigator in the FreeOAB clinical study and urologist at Ochsner Health in New Orleans, will present evidence in support of the safety and efficacy of a new therapy and digital behavioral support system to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI).
The Vivally™ System is a wearable bladder control therapy and digital health system utilizing neuromodulation to treat patients with the chronic conditions of overactive bladder (OAB) and urge urinary incontinence (UUI) and their associated symptoms including urinary urgency, urinary frequency, and urge urinary incontinence, without the need for surgery, permanent implants, or drugs. The non-invasive therapy and digital health system is intended to provide personalized treatment with the ability to conduct therapy at home, in as little as 30 minutes per week. The Vivally System features patented closed-loop control technology that uses the patient’s own physiologic response to objectively confirm activation of the tibial nerve and continuously monitor nerve recruitment, automatically adjusting the stimulation within a personalized therapeutic range set by the physician, for each patient, to ensure both comfort, and optimal therapeutic output.
Jill Schiaparelli, Avation’s CEO commented “Avation Medical is a strong team of professionals that is committed to making neuromodulation more accessible to patients suffering from chronic conditions like OAB through its wearable therapy and digitally enabled behavioral support platform. We are honored that Dr. Goudelocke will present this groundbreaking evidence on behalf of the investigators.”